D-Glutamine

Generic Name: D-Glutamine

Brand Names: Endari

Drug Type: Small Molecule

Chemical Formula: C_₅H_₁₀N_₂O_₃

CAS Number: 5959-95-5

Unique Ingredient Identifier: 63HB36CA2Y

Overview

A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells.

Background

Indication

Used for nutritional supplementation, also for treating dietary shortage or imbalance. Used to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older .

Associated Conditions

Osteoporosis
Acute Complications of Sickle Cell Disease

New Sickle Cell Disease Therapies Expand Options, But Access Barriers Remain

5 days ago

Recent FDA approvals have expanded treatment options for sickle cell disease beyond hydroxyurea, including L-glutamine, crizanlizumab, and two gene therapies, marking significant progress in disease management.

Fremanezumab Shows Dual Efficacy in Treating Both Migraine and Depression in Landmark Trial

21 days ago

A groundbreaking clinical trial demonstrates that fremanezumab, a CGRP-targeting monoclonal antibody, significantly reduces both migraine frequency and depressive symptoms in patients with comorbid conditions.

Novel Metabolic Signatures Show Promise for Earlier Pancreatic Cancer Detection and Prognosis

5 months ago

Researchers have identified distinct metabolic signatures in pancreatic cancer patients using quantitative mass spectrometry, potentially offering new pathways for earlier diagnosis and survival prediction.

AND017 Receives FDA Orphan Drug Designation for Sickle Cell Disease

7 months ago

Kind Pharmaceuticals' AND017, an oral small molecule, has been granted orphan drug status by the FDA for the treatment of sickle cell disease (SCD).

FDA Grants Orphan Drug Designation to AND017 for Sickle Cell Disease

7 months ago

The FDA has granted Orphan Drug Designation to AND017, a novel hemoglobin-elevating agent developed by Kind Pharmaceutical, for the treatment of sickle cell disease (SCD).

Drug Development Updates